CARsgen Completes Series A Financing
2014年11月26日
SHANGHAI,?Nov. 26, 2014?/PRNewswire/ -- CARsgen, a leader in the development of Chimeric Antigen Receptors T (CAR-T) cell immunotherapy to treat a variety of cancers, today announced the completion of a series A financing led by BVCF, a?China-based healthcare private equity fund.